Trade Vir Biotechnology, Inc. - VIR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 8.09 |
| Open | 8.04 |
| 1-Year Change | -69.02% |
| Day's Range | 7.99 - 8.19 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2024 | 8.00 | -0.08 | -0.99% | 8.08 | 8.25 | 7.98 |
| Apr 23, 2024 | 8.09 | 0.02 | 0.25% | 8.07 | 8.25 | 8.00 |
| Apr 22, 2024 | 8.06 | 0.10 | 1.26% | 7.96 | 8.35 | 7.87 |
| Apr 19, 2024 | 7.91 | -0.03 | -0.38% | 7.94 | 8.16 | 7.72 |
| Apr 18, 2024 | 7.92 | -0.21 | -2.58% | 8.13 | 8.23 | 7.90 |
| Apr 17, 2024 | 8.22 | -0.13 | -1.56% | 8.35 | 8.49 | 8.16 |
| Apr 16, 2024 | 8.32 | -0.13 | -1.54% | 8.45 | 8.52 | 8.30 |
| Apr 15, 2024 | 8.52 | -0.36 | -4.05% | 8.88 | 8.94 | 8.40 |
| Apr 12, 2024 | 8.91 | -0.26 | -2.84% | 9.17 | 9.18 | 8.80 |
| Apr 11, 2024 | 9.20 | 0.12 | 1.32% | 9.08 | 9.35 | 8.97 |
| Apr 10, 2024 | 9.03 | -0.16 | -1.74% | 9.19 | 9.22 | 8.98 |
| Apr 9, 2024 | 9.49 | 0.03 | 0.32% | 9.46 | 9.86 | 9.40 |
| Apr 8, 2024 | 9.44 | 0.16 | 1.72% | 9.28 | 9.45 | 9.18 |
| Apr 5, 2024 | 9.31 | 0.06 | 0.65% | 9.25 | 9.42 | 9.12 |
| Apr 4, 2024 | 9.41 | -0.33 | -3.39% | 9.74 | 9.84 | 9.40 |
| Apr 3, 2024 | 9.64 | 0.25 | 2.66% | 9.39 | 9.65 | 9.23 |
| Apr 2, 2024 | 9.57 | -0.24 | -2.45% | 9.81 | 9.87 | 9.56 |
| Apr 1, 2024 | 10.16 | 0.05 | 0.49% | 10.11 | 10.20 | 9.87 |
| Mar 28, 2024 | 10.08 | -0.02 | -0.20% | 10.10 | 10.30 | 9.98 |
| Mar 27, 2024 | 10.06 | 0.12 | 1.21% | 9.94 | 10.20 | 9.74 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Vir Biotechnology Company profile
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license, and option agreement Visterra, Inc.; license agreement with The Rockefeller University and MedImmune, Inc.; and collaboration with WuXi Biologics and Alnylam Pharmaceuticals, Inc. The company has a research collaboration agreement with the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and Vaccine Research Center to advance characterization and development of human monoclonal antibodies against coronaviruses. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.| Industry: | Biotechnology & Medical Research (NEC) |
1800 Owens Street
Suite 900
SAN FRANCISCO
CALIFORNIA 94158
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com